Wave Life Sciences Ltd. Ordinary Shares - WVE STOCK NEWS

Wave Life Sciences Ltd. (Nasdaq: WVE) has announced results from its PRECISION-HD trials, revealing no significant efficacy for investigational treatments WVE-120102 and WVE-120101 in reducing mutant huntingtin protein (mHTT) in Huntington's disease patients. Consequently, clinical development for both candidates will be halted. However, the company is advancing its novel WVE-003 program with improvements in pharmacology and allele-selectivity targeted at SNP3. Wave plans to initiate dosing for WVE-003 in 2021, showcasing commitment to developing therapies that spare healthy wild-type huntingtin protein.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno and CMO Michael Panzara will participate in a virtual fireside chat at the Third Annual Stifel CNS Day on April 1, 2021, at 11:30 a.m. ET. Investors can access the presentation live via the company's investor relations page, with a replay available for 90 days afterward. Wave Life Sciences focuses on developing genetic medicines through its proprietary PRISM platform, targeting a range of genetically defined diseases.

Wave Life Sciences (WVE) reported a $28.8 million net loss for Q4 2020, down from $56.8 million in Q4 2019. For the full year, net loss was $149.9 million, improved from $193.6 million. R&D expenses decreased to $30 million in Q4 2020 from $49.1 million in Q4 2019, driven by cost reductions. Wave plans to advance five clinical programs in 2021, including novel therapies for Huntington’s disease and ALS. The company ended 2020 with $184.5 million in cash, projected to last into Q2 2023.

Wave Life Sciences (Nasdaq: WVE) announced a live webcast and conference call scheduled for March 4, 2021, at 8:00 a.m. ET to discuss its fourth quarter and full year 2020 financial results. The company focuses on developing innovative genetic medicines using proprietary technology aimed at treating genetically defined diseases. Investors can access the call via the company's Investor Relations page or by phone. An archived version will be available post-call.

Wave Life Sciences (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 5:00 p.m. ET. The event will be accessible via a live webcast on the company's investor relations page, with a replay available for 90 days post-event. Wave Life Sciences focuses on developing innovative therapies for genetically defined diseases through its proprietary PRISM platform, aiming to create effective treatments and improve patient outcomes.

Wave Life Sciences (Nasdaq: WVE) announced key milestones for 2021, including the initiation of three clinical trials utilizing novel PN backbone chemistry. These studies will target Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, and Duchenne muscular dystrophy. Data from ongoing PRECISION-HD trials for Huntington’s disease is expected by the end of Q1 2021, aiding potential Phase 3 decision-making. Wave's proprietary PRISM platform continues to advance, with in vivo data for alpha-1 antitrypsin deficiency anticipated in the first half of 2021.

Wave Life Sciences Ltd. (Nasdaq: WVE) has appointed Jonathan Rosin as the new Chief Human Resources Officer (CHRO). With over 25 years of HR experience, Rosin aims to enhance Wave's clinical trial support and organizational development. His prior role as CHRO at Ironwood Pharmaceuticals involved significant cultural and capability advancements. Rosin received stock options for 53,000 shares and 27,000 restricted shares as part of his compensation. This strategic leadership change intends to foster growth and maintain Wave's unique culture while advancing their drug development efforts.

Wave Life Sciences Ltd. (Nasdaq: WVE) is set to present at the 29th Annual Credit Suisse Healthcare Conference on November 11, 2020, at 5:00 p.m. ET. Dr. Paul Bolno, President and CEO, will deliver the presentation. A live webcast can be accessed through the company's Investor Relations page, with a recording available for 60 days post-event. Wave Life Sciences focuses on developing innovative genetic treatments using its proprietary PRISM platform to design and optimize stereopure oligonucleotides, addressing various genetically defined diseases.

Wave Life Sciences Ltd. (WVE) reported its third quarter 2020 financial results, highlighting a cash balance of $216.4 million. The company is advancing several clinical trials, including WVE-003 for Huntington's disease and WVE-004 for ALS, with clinical trial applications expected in early 2021. Wave announced its first ADAR editing program targeting alpha-1 antitrypsin deficiency. R&D expenses decreased to $28.3 million from $44.6 million in Q3 2019, while the net loss narrowed to $33.1 million. The company anticipates funding through mid-2023 after a $93.7 million capital raise.